AstraZeneca: Solid Results, But Risks Emerge (Rating Downgrade)

Group 1 - AstraZeneca PLC reported strong Q3 2025 and 9M 2025 results, indicating healthy growth trends continuing from H1 2025 [1] - The positive outlook for 2025 aligns with the company's performance expectations [1] Group 2 - Manika, a macroeconomist with over 20 years of experience, focuses on investment opportunities in the green economy through her profile Long Term Tips [2] - Her investing group, Green Growth Giants, explores deeper opportunities within the green economy segment [2]